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In order to develop clinical diagnostic tools for rapid detection of SARS-CoV (se-
vere acute respiratory syndrome-associated coronavirus) and to identify candidate
proteins for vaccine development, the C-terminal portion of the nucleocapsid (NC)
gene was amplified using RT-PCR from the SARS-CoV genome, cloned into a yeast
expression vector (pEGH), and expressed as a glutathione S-transferase (GST) and
Hisx6 double-tagged fusion protein under the control of an inducible promoter.
Western analysis on the purified protein confirmed the expression and purification
of the NC fusion proteins from yeast. To determine its antigenicity, the fusion pro-
tein was challenged with serum samples from SARS patients and normal controls.
The NC fusion protein demonstrated high antigenicity with high specificity, and
therefore, it should have great potential in designing clinical diagnostic tools and
provide useful information for vaccine development.
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Introduction
The global outbreak of severe acute respiratory syn-
drome (SARS) in Year 2003 has posted a great threat
to the public health (1-3). Recently, several lines of
evidence have demonstrated that a new strain of coro-
naviruses is the causal pathogen of this infectious dis-
ease (4-6). Some research groups managed to rapidly
decode the genome of the virus from couples of clinical
isolates worldwide (7-9), thus, provided the founda-
tion for further analyzing its pathogenicity and the
development of effective diagnostic tools and thera-
peutics.
Coronaviruses produce at least four structural pro-
teins, namely S (spike), M (membrane), E (envelope),
and N (nucleocapsid). Antigenicity studies in the
avian infectious bronchitis virus indicated that the N





protein is one of the immunodominant antigens
that induce cross-reactive antibodies in high titers,
whereas the S glycoprotein induces serotype-specific
and cross-reactive antibodies (10). It has also been
reported that the N protein from porcine reproduc-
tive and respiratory syndrome (PRRS) virus is the
major immunogen of the virus. Several domains of
antigenic importance in the N protein were identified
by monoclonal antibodies raised against PRRS virus
(11-13). Interestingly, deletion of the 11 amino acids
from the C-terminus of the N protein (NC) disrupted
the epitope configuration recognized by all of the
conformation-dependent monoclonal antibodies (13);
amino acid substitution within the C-terminal domain
revealed that the secondary structure of the domain is
an important determinant of conformational epitope
formation (14).
Wang et al. recently reported that the N protein
could be one of the major antigens of SARS-CoV.
Specially, two peptides located at the C-terminal re-
gion of the N protein of SARS-CoV could be recog-
nized by the antisera from SARS patients (Wang et
al., in press). In this study, the coding region of the
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C-terminal portion of the N protein was cloned as
GST-Hisx6 (Glutathione S-transferase Histidine) fu-
sion and the peptide was expressed in yeast. The
purified fusion protein showed positive signals when
probed with sera from SARS patients in Western anal-
ysis. Using the ELISA (Enzyme-Linked Immunosor-
bent Assay) approach, the purified fusion protein was
shown to specifically recognize the sera from SARS
patients, but not those from the negative controls.
Results
Purification and characterization of the
NC fusion protein
The RT-PCR product of the NC segment from Isolate
BJ01 was cloned into pGEM-T vector. The recombi-
nant pGEM-T was further PCR amplified with the
yeast-cloning primer pair. After verification by DNA
sequencing, the PCR product was co-transformed into
yeast with the linearized pEGH vector, and the yeast
transformants were selected on proper media. The re-
sulting recombinant plasmids were rescued into bac-
teria, and named as pEGH-NC. The pEGH-NC con-
structs were restricted with EcoR I to determine
whether their inserts were in the right sizes (Figure
1A). Confirmed plasmids were further analyzed with
DNA sequencing to validate their identities and read-
ing frames.
The confirmed plasmids were re-introduced into
yeast cells for the production of the GST-Hisx6-NC
fusion protein. Probed with anti-Hisx6 antibodies in
a Western analysis, the lysate of the induced yeast
cells emerged a band with the expected molecular
weight of the fusion protein, which is absent in the
control carrying the empty vector, indicating that the
NC fragment was specifically expressed in the proper
yeast strains (Figure 1B). Using the GST affinity
tag, the fusion protein was purified using glutathione
agarose beads, and separated by SDS-PAGE (SDS-
Polyacrylamide Gel Electrophoresis). Coomassie Blue
staining (Figure 1C) demonstrated that the fusion
protein was purified with high quality and purity
without any detectable contamination.
Immunoreactions of the NC fusion pro-
tein
The purified fusion protein was transferred onto a
PVDF (Polyvinylidene Fluoride) membrane, probed
Fig. 1 Characterization of the NC fragment. A. EcoR
I-digested pEGH-NC showed the NC fragment as ex-
pected size. B. Western analysis with anti-Hisx6 antibody
demonstrated that the NC fragment expressed as the ex-
pected molecular weight in the yeast cells with pEGH-NC
(+) but not in the control (−). C. The purified NC fusion
protein with the GST affinity tag stained by Coomassie
Blue. Arrows indicate the expected NC fragment, and
the molecular weight markers are indicated.
with antisera from SARS patients, and detected with
anti-human IgG secondary antibodies. The results
further confirmed the immunoreactivity of the ex-
pressed fusion protein (Figure 2), which was immuno-
logically interactive with sera from two individual
SARS patients. The GST-His-NC fusion protein gave
a specific band different from the normal GST-His
fusion protein, and the lysate of Vero-6 cell culture
containing SARS-CoV (L-S), as the positive control,
showed a strong band of approximately 50 kDa.
Fig. 2 Immunoreactivity of the purified GST-His-NC fu-
sion protein with antisera from SARS patients. Two inde-
pendent antisera (A and B) were used for the experiment.
Arrows indicate the positions of the GST-His-NC fusion
protein. Molecular weights were marked in between the
two panels of the blots. L-S: lysate of Vero-6 cell culture
containing SARS-CoV.
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A potential diagnostic tool for SARS
Since the ELISA approach is widely used in clini-
cal diagnostics, we decided to present NC proteins
in an ELISA format and determine whether it is use-
ful as a potential detection tool in clinical diagnos-
tics. The purified NC fusion protein was embedded
in a 96-well ELISA plate and incubated with the sera
taken from four individual SARS patients and four
normal controls. The results showed that the NC
fusion protein could specifically distinguish the sera
from SARS patients (sera +) and those from normal
controls (sera −) with a significant statistical differ-
ence (Figure 3). In contrast, no significant difference
has been observed between the results obtained with
the NC fusion protein and with the L-S.
Fig. 3 ELISA analysis of the NC fusion protein as a po-
tential diagnostic tool against SARS. The O.D. (450 nm)
values are indicated as the light bars (the NC fusion pro-
tein) and the dark bars (the Vero-6 cell lysate containing
SARS-CoV), respectively.
Discussion
The analysis of the structure and function of the N
protein in SARS-CoV should be beneficial to under-
stand the life cycle and pathogenicity of the virus
(15). Genetically engineered peptides would be one
of the best ways to identify the genomic segment as-
sociated with the antigenicity and to develop vaccines
defended against SARS. Of various methods to over-
produce proteins of interest, the yeast system was cho-
sen to express the fusion protein based mainly on two
major considerations. First, the cloning procedure is
simplified by taking advantage of the homologous re-
combination cloning strategy in yeast because it is
a restriction and ligation reaction-free system, which
remarkably simplifies cloning procedures. Secondly,
most posttranslational modifications, such as glycosy-
lation and phosphorylation, could be reserved in the
eukaryotic expression system (16). These properties
may play an important role in immunoreaction. Our
data provided firm evidence that the antigenicity of
the N protein was well preserved in the NC fusion
protein.
The N gene is located towards the 3′ terminal part
of the SARS-CoV genome. According to the “co-
terminal model” that all the subgenomic RNA tran-
scripts have the same 3′ part at its end with the same
polyadenylation site (7), the number of transcripts of
the N protein would be dramatically larger than all
the upstream genes. This model was established for
other coronaviruses and recently confirmed by North-
ern analysis of the SARS-CoV-containing Vero-6 cells
using a 3′ terminal probe (7). If the co-terminal
model is correct, the N gene in all other 3′ co-terminal
subgenomic transcripts would be translated into huge
amount of the N protein in addition to the N-specific
transcripts, unless a possible mechanism stop or in-
hibit the ribosome binding site of the gene from trans-
lation with the subgenomic transcripts.
It is obvious that when the virus invades the host
cells, it may not carry any N proteins outside the viri-
ons, even though a specific or non-specific attachment
could not be easily excluded. There are only two pos-
sible reasons why the N protein is freely exposed to the
host immune system. First, the virus collapses after
injecting its genome into the host cells. Second, the
extra N protein, after binding to the genomic RNA
in a fixed molecular ratio, would not be packaged by
the cellular liquid bilayer membrane and therefore re-
mains in the cytoplasm. When the host cells collapse,
the N protein is released. The most possible mecha-
nism is that the N protein is engulfed by the antigen
presenting cells (APC) and presented to T cells for
the adaptive immunity. Whether the N protein is in-
volved in the process of the innate immunity remains
to be revealed.
Since the N protein has been shown important in
many ways, we decided to focus on this protein as
an initial step towards better understanding of the
mechanism(s) of the disease. Using yeast recombina-
tion cloning strategy, we were able to rapidly clone
and purify the C-terminal fragment of the N protein
from yeast cells. Both Western and ELISA analy-
ses demonstrated that the N protein fragment ren-
der highly specific immuno-response in the SARS pa-
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tients. The ultimate goal of our study is to provide
new tools for the campaign against SARS. The cloning
and expression of the antigenic fragment of the virus
is more advantageous and safer than the method using
the whole virus lysate in large-scale production of the
antigen and vaccine. The immunoreaction of the NC
fusion protein with SARS sera indicates that the NC
fusion protein may be of great potential in designing
clinical diagnostic tool for the rapid and on-site iden-
tification of SARS patients, and further more, may
become a candidate for the vaccine against SARS.
Materials and Methods
The sera from SARS patients and normal controls
were provided by the Department of Immunoassay,
Beijing Genomics Institute (BGI). The Vero-6 cell
lysate containing coronaviruses was kindly provided
by Institute of Microbiology and Epidemiology, Chi-
nese Academy of Militarily Medical Sciences. Yeast
Strain Y258 and the yeast expression vector, pEGH,
were gifts from Dr. Michael Snyder at Yale University.
Primer design and fragment cloning
The NC-specific primer pair (NCF: AAAGGA-
CAAAAAGAAAAAGACT; NCR: AATTTTACAC-
ATTAGGGCTCTTC), corresponding to the segment
between Codons 371 and 422 in the N gene, was
designed based on the consensus sequences of Iso-
lates BJ01-BJ04 of SARS-CoV contributed by BGI
(GenBank accession numbers: AY278488; AY278487;
AY278490; AY279354). The nucleotide positions
(29,211-29,369) refer to the complete genome se-
quence of BJ01. The yeast-cloning primer pair was de-
signed by attaching the vector sequences of pEGH to
the gene-specific priming sites as described by Zhu et
al. (17), and synthesized by Shanghai DNA BioTech-
nologies Company.
The extraction of viral RNA, RT-PCR, the cloning
of PCR product into pGEM-T plasmid, yeast cul-
ture and competent cell preparation, transforma-
tion, and plasmid rescue were performed as de-
scribed previously (18, 19). Briefly, the RT-PCR
product was amplified using the NC primer pair
and cloned into pGEM-T. The recombinant pGEM-
T plasmid was used as the template for PCR with
the yeast-cloning primer pair, and the PCR product
was co-transformed into yeast competent cells with
HindIII/XbaI-linearized pEGH vector (17). The cor-
rect reading frame in the recombinant vector was con-
firmed by sequencing through the junction between
the vector and insert. The induction, expression and
purification of the fusion protein were carried out fol-
lowing the standard protocol (17).
Western blot and ELISA analysis
Protein extracted from yeast cells were separated by
SDS-PAGE (10%) and transferred onto PVDF mem-
branes. The membranes were blocked with milk,
rinsed twice with TTBS (Tris 100 mM, NaCl 120 mM,
0.1% Tween-20, pH 7.9) and incubated in TTBS with
3% BSA containing either anti-Hisx6 (Pierce, Rock-
ford, USA) or sera from SARS patients as primary
antibody at room temperature for 2 h or at 4˚C
overnight. After the membranes were washed with
TTBS three times (5 min each), the secondary anti-
body was added in TTBS with 3% BSA at room tem-
perature for 1 h. Alkaline phosphatase labeled anti-
rabbit IgG (Pierce) and goat anti-human IgG (Bei-
jing Zhongshan Company) were used as secondary
antibody to detect Hisx6 and human antibodies, re-
spectively. The results were visualized by incubating
the membrane with the mixture of NBT and BCIP
(Promega, Madison, USA) for 5-10 min.
ELISA experiments were carried out using conven-
tional protocol. In brief, the purified fusion protein
was mixed with sample dilution buffer, embedded in
a 96-well ELISA plate, and incubated at 37˚C for
30 min. The wells were then washed five times with
washing buffer, and incubated with sera from either
SARS patients or normal controls. Working enzyme
tracer was added into each well to monitor the bind-
ing of the fusion protein and antibodies. The signals
were then detected at 450 nm by an ELISA reader
(Bio-Rad, Hercules, USA).
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